A phase II study of ixabepilone (BMS-247550) in patients with metastatic breast cancer previously treated with an Anthracycline and who are Taxane resistant

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220193

Enrollment

Registered

2005-12-21

Start date

2005-12-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic breast cancer

Interventions

investigational material(s) Generic name etc : ixabepilone (BMS-247550) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investig

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Diagnosis of histologically-confirmed, metastatic or advanced breast cancer. 2. Presence of at least one unidimensionally measurable disease. 3. No more than three prior chemotherapy regimens for metastatic disease. 4. Patients with metastatic breast cancer previously treated with an Anthracycline and who are resistant to Taxane. 5. Performance status 0 - 1.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Efficacy: response rate, duration of observed response Safety: incidence rates and severity of observed adverse events	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026